HIV/AIDS Treatment

New data suggest potential for once-daily dosing regimen of Kaletra

Published in Cancer Weekly, March 9th, 2004

New data, presented at a scientific meeting in San Francisco, California, suggest that an HIV treatment regimen based on a once-daily dose of Abbott Laboratories' protease inhibitor Kaletra (lopinavir/ritonavir) had comparable viral suppression when compared to a twice-daily dose through 1 year (48 weeks) in patients new to treatment.

Currently, the adult recommended dosage of Kaletra is 400/100 mg (3 capsules or 5 milliliters) twice daily with food.

"Patients taking a once-daily Kaletra-based regimen showed comparable results to the twice-daily regimen in terms of virologic suppression," said Joseph Gathe, Jr., MD, FACP, lead investigator and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-03-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry